WO2007047551A3 - Methods and compositions for derepression of iap-inhibited caspase - Google Patents

Methods and compositions for derepression of iap-inhibited caspase Download PDF

Info

Publication number
WO2007047551A3
WO2007047551A3 PCT/US2006/040301 US2006040301W WO2007047551A3 WO 2007047551 A3 WO2007047551 A3 WO 2007047551A3 US 2006040301 W US2006040301 W US 2006040301W WO 2007047551 A3 WO2007047551 A3 WO 2007047551A3
Authority
WO
WIPO (PCT)
Prior art keywords
tpi
iap
inhibited caspase
derepression
compositions
Prior art date
Application number
PCT/US2006/040301
Other languages
French (fr)
Other versions
WO2007047551A2 (en
Inventor
John C Reed
Richard A Houghten
Adel Nefzi
John M Ostresh
Clemencia Pinilla
Kate Welsh
Original Assignee
Burnham Inst
Torrey Pines Inst
John C Reed
Richard A Houghten
Adel Nefzi
John M Ostresh
Clemencia Pinilla
Kate Welsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst, Torrey Pines Inst, John C Reed, Richard A Houghten, Adel Nefzi, John M Ostresh, Clemencia Pinilla, Kate Welsh filed Critical Burnham Inst
Priority to EP06825997A priority Critical patent/EP1951278A4/en
Publication of WO2007047551A2 publication Critical patent/WO2007047551A2/en
Publication of WO2007047551A3 publication Critical patent/WO2007047551A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Abstract

The invention provides isolated agents having a core peptide selected from the group consisting of Core peptides 5 through 39 and 42 through 55, wherein the agent derepresses an IAP-inhibited caspase. Also provided is an isolated agent having a core structure selected from any of the structures shown in Figures 5, 9, 10, 14B, 21-24 and 48, a core structure selected from the group of TPI 759, TPI 882, TPI 914 or TPI 927; and a core structure from a library selected from TPI 1391, TPI 1349, TPI 1396, TPI 1509, TPI 1540, TPI 1400, TPI 792, TPI 1332, TPI 1567, TPI 1576 and TPI 1577, wherein the agent derepresses an IAPinhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase.
PCT/US2006/040301 2005-10-14 2006-10-13 Methods and compositions for derepression of iap-inhibited caspase WO2007047551A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06825997A EP1951278A4 (en) 2005-10-14 2006-10-13 Methods and compositions for derepression of iap-inhibited caspase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/251,617 2005-10-14
US11/251,617 US20060258581A1 (en) 2001-11-21 2005-10-14 Methods and composition for derepressions of IAP-inhibited caspase

Publications (2)

Publication Number Publication Date
WO2007047551A2 WO2007047551A2 (en) 2007-04-26
WO2007047551A3 true WO2007047551A3 (en) 2007-06-21

Family

ID=37963154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040301 WO2007047551A2 (en) 2005-10-14 2006-10-13 Methods and compositions for derepression of iap-inhibited caspase

Country Status (3)

Country Link
US (1) US20060258581A1 (en)
EP (1) EP1951278A4 (en)
WO (1) WO2007047551A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
EP1851200B1 (en) 2005-02-25 2014-01-15 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2006122408A1 (en) * 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP2009512719A (en) * 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド IAPBIR domain binding compound
TWI504597B (en) * 2006-03-16 2015-10-21 Pharmascience Inc Iap bir domain binding compounds
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
JP5452223B2 (en) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション IAP inhibitor
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
BRPI0715195A2 (en) * 2006-07-24 2013-06-11 Tetralogic Pharm Corp compound, methods for inducing and stimulating apoptosis in a cell, for enhancing apoptosis of pathogenic cells in vivo in an individual, and for treating a disease, and, pharmaceutical composition.
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
EP2310402A1 (en) * 2008-06-27 2011-04-20 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
ES2625637T3 (en) 2010-02-12 2017-07-20 Pharmascience Inc. BIR IAP domain binding compounds
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006180A (en) * 1973-10-12 1977-02-01 Merck & Co., Inc. [1,3-Dihydroxy-2-substituted and 2,2-disubstituted-indanyloxy(or thio)]alkanoic acids
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1992009300A1 (en) * 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
US5766848A (en) * 1993-01-04 1998-06-16 Synaptic Pharmaceutical Corporation Methods for identifying compounds which specifically bind a human betaine/GABA transporter
US6228603B1 (en) * 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
US6159709A (en) * 1998-07-24 2000-12-12 Apoptogen, Inc. XIAP IRES and uses thereof
ATE321751T1 (en) * 1999-07-28 2006-04-15 Kirin Brewery UREA DERIVATIVES AS CCR-3 RECEPTOR INHIBITORS
US20050119176A1 (en) * 2001-11-21 2005-06-02 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
CN101029080A (en) * 2001-11-21 2007-09-05 伯纳姆研究院 Methods and compositions for derepression of IAP-inhibited caspase
WO2006102068A2 (en) * 2005-03-17 2006-09-28 The Burnham Institute Methods and compositions for derepression of iap-inhibited caspase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1951278A4 *

Also Published As

Publication number Publication date
US20060258581A1 (en) 2006-11-16
EP1951278A4 (en) 2010-07-07
WO2007047551A2 (en) 2007-04-26
EP1951278A2 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
WO2007047551A3 (en) Methods and compositions for derepression of iap-inhibited caspase
AU2001267039A1 (en) Methods for forming rough ruthenium-containing layers and structures/methods using same
AU2001290903A1 (en) Multi-layered structures and methods for manufacturing the multi-layered structures
AU2003277103A1 (en) Creamer compositions and methods of making and using the same
AU2001296724A1 (en) Microelectronic magnetic structure, device including the structure, and methods of forming the structure and device
AU2002305833A1 (en) Methods and compositions for helping the body resist the effects of the aging process
AU2002312097A1 (en) Methods and systems for metered raffle-style gaming
AU2002360679A1 (en) Card game and method of playing the same
WO2003080024A3 (en) Nanoparticulate compositions of map kinase inhibitors
AU2002352950A1 (en) Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
IL160630A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PL370275A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003045974A3 (en) Methods and compositions for derepression of iap-inhibited caspase
AU2001268138A1 (en) Method of performing distributed load testing
AU2002254181A1 (en) Methods and compositions for the construction and use of fusion libraries
AUPR907101A0 (en) An electromechanical actuator and methods of providing same
EP1422297A4 (en) Method of testing for bronchial asthma
AU2002367881A1 (en) Gmr spin valve structure using heusler alloy
AU2002360244A1 (en) Test structures and models for estimating the yield impact of dishing and/or voids
AU2003221138A1 (en) Enameled wire having magnetic reluctance properties and preparation method thereof, and coil using the same and preparation method thereof
AU2002243714A1 (en) Word game and methods for conducting same
AU2002233530A1 (en) Multiple-stage game of chance and method of and system for playing the game
AU2002367129A1 (en) Organ fibrosis inhibitors
AU2001225624A1 (en) War game complex and method of playing the game
EP1197760A3 (en) Suppression of the effect of residual magnetization in MRI

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006825997

Country of ref document: EP